Overview

Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride